肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 ESMO/EURACAN临床实践指南：睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访

2022-01-17 欧洲肿瘤内科学会 Ann Oncol

泌尿生殖系肿瘤睾丸精原细胞癌非精原细胞癌

2022年1月，欧洲肿瘤内科学会(ESMO)发布了睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访指南，指南提供了睾丸精原细胞癌和非精原细胞的管理建议，内容涉及诊断、治疗和随访。

中文标题：

2022 ESMO/EURACAN临床实践指南：睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访

英文标题：

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

发布机构：

欧洲肿瘤内科学会

发布日期：

2022-01-17

简要介绍：

2022年1月，欧洲肿瘤内科学会(ESMO)发布了睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访指南，指南提供了睾丸精原细胞癌和非精原细胞的管理建议，内容涉及诊断、治疗和随访。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 ESMO_EURACAN临床实践指南：睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9c9571c0023388a3, title=2022 ESMO/EURACAN临床实践指南：睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访, enTitle=Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up, guiderFrom=Ann Oncol, authorId=0, author=, summary=2022年1月，欧洲肿瘤内科学会(ESMO)发布了睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访指南，指南提供了睾丸精原细胞癌和非精原细胞的管理建议，内容涉及诊断、治疗和随访。, cover=https://img.medsci.cn/2022124/1643022621653_1608702.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Mon Jan 17 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年1月，欧洲肿瘤内科学会(ESMO)发布了睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访指南，指南提供了睾丸精原细胞癌和非精原细胞的管理建议，内容涉及诊断、治疗和随访。</span></p>, tagList=[TagDto(tagId=117298, tagName=泌尿生殖系肿瘤), TagDto(tagId=122121, tagName=睾丸精原细胞癌), TagDto(tagId=122122, tagName=非精原细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5103, appHits=118, showAppHits=0, pcHits=712, showPcHits=4984, likes=2, shares=27, comments=5, approvalStatus=1, publishedTime=Tue Jan 25 15:14:00 CST 2022, publishedTimeString=2022-01-17, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Mon Jan 24 19:12:29 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 09:15:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 ESMO_EURACAN临床实践指南：睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访.pdf)])
2022 ESMO_EURACAN临床实践指南：睾丸精原细胞癌和非精原细胞癌的诊断，治疗和随访.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1188434, encodeId=77ce118843434, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4b6483849, createdName=ms4000002110537530, createdTime=Wed Jan 26 22:52:16 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188235, encodeId=590f1188235f2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35826479110, createdName=ms6000001261334118, createdTime=Wed Jan 26 10:13:37 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188218, encodeId=e2101188218b4, content=学到很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=286e6451128, createdName=ms6000001409755765, createdTime=Wed Jan 26 09:00:30 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188112, encodeId=bfbb118811268, content=学到了很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae476392472, createdName=ms6000001920279869, createdTime=Tue Jan 25 20:56:26 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-26 ms4000002110537530

    学到了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1188434, encodeId=77ce118843434, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4b6483849, createdName=ms4000002110537530, createdTime=Wed Jan 26 22:52:16 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188235, encodeId=590f1188235f2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35826479110, createdName=ms6000001261334118, createdTime=Wed Jan 26 10:13:37 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188218, encodeId=e2101188218b4, content=学到很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=286e6451128, createdName=ms6000001409755765, createdTime=Wed Jan 26 09:00:30 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188112, encodeId=bfbb118811268, content=学到了很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae476392472, createdName=ms6000001920279869, createdTime=Tue Jan 25 20:56:26 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-26 ms6000001261334118

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1188434, encodeId=77ce118843434, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4b6483849, createdName=ms4000002110537530, createdTime=Wed Jan 26 22:52:16 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188235, encodeId=590f1188235f2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35826479110, createdName=ms6000001261334118, createdTime=Wed Jan 26 10:13:37 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188218, encodeId=e2101188218b4, content=学到很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=286e6451128, createdName=ms6000001409755765, createdTime=Wed Jan 26 09:00:30 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188112, encodeId=bfbb118811268, content=学到了很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae476392472, createdName=ms6000001920279869, createdTime=Tue Jan 25 20:56:26 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-26 ms6000001409755765

    学到很多

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1188434, encodeId=77ce118843434, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4b6483849, createdName=ms4000002110537530, createdTime=Wed Jan 26 22:52:16 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188235, encodeId=590f1188235f2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35826479110, createdName=ms6000001261334118, createdTime=Wed Jan 26 10:13:37 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188218, encodeId=e2101188218b4, content=学到很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=286e6451128, createdName=ms6000001409755765, createdTime=Wed Jan 26 09:00:30 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188112, encodeId=bfbb118811268, content=学到了很多, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae476392472, createdName=ms6000001920279869, createdTime=Tue Jan 25 20:56:26 CST 2022, time=2022-01-25, status=1, ipAttribution=)]
    2022-01-25 ms6000001920279869

    学到了很多

    0

相关指南

2021 SFRO指南：前列腺癌近距离放射治疗

法国放射肿瘤学学会(SFRO,French society for radiation oncology) · 2021-12-22

中国前列腺癌筛查与早诊早治指南（2022，北京）

国家癌症中心 · 2022-01-05

2021 SFRO建议：放射治疗在膀胱癌管理中的作用

法国放射肿瘤学学会(SFRO,French society for radiation oncology) · 2021-12-23

2021 EAU指南：帕博利珠单抗辅助治疗肾细胞癌（更新）

欧洲泌尿外科学会(EAU,European Association of Urology) · 2021-12-14

2021更新版—2020 NICE指南：前列腺癌（NG.131）

英国国家卫生与临床优化研究所 (NICE,National Institute for Health and Clinical Excellence) · 2021-12-15

肾上腺皮质癌诊治专家共识

中国医师协会泌尿外科分会 · 2021-11-15